LENZ Therapeutics, Inc. (LENZ) · Oct 28, 2026 · Earnings
Miss — Q3 revenue $3.38M vs ~$4.20M consensus; EPS -$0.99 vs ~-$0.97 consensus
LENZ earnings show faster VIZZ adoption, but revenue missed consensus as the company announced a major cost reduction and CEO transition.
LENZ is in the early commercialization phase of VIZZ, its only marketed product, using telehealth, ePharmacy access and consumer advertising to build demand for a new presbyopia treatment. The company launched telehealth in July 2026 and has been carrying heavy commercial spending while trying to convert awareness into repeat prescriptions.
| Metric | Q3 2026 | Q3 2025 / consensus | Read |
|---|---|---|---|
| Product sales | $2.6M | $0 / not separately estimated | Up 50% sequentially |
| Total revenue | $3.384M | $12.500M / ~$4.20M consensus | Miss |
| Net loss per share | $(0.99) | $(0.59) / ~$(0.97) consensus | Slight miss |
| SG&A expense | $35.848M | $27.596M | Still rising |
| Cash and cash equivalents | $30.553M | $25.179M at Dec. 31, 2025 | Higher |
| Marketable securities | $166.750M | $267.168M at Dec. 31, 2025 | Lower |
The commercial signal improved, but the earnings result missed. VIZZ product sales reached $2.6 million on more than 38,000 paid prescriptions, up approximately 50% and 51% from the second quarter, respectively. More than 60% of ePharmacy patients have purchased multiple monthly packs, supporting the idea that retention is not the immediate problem. 〔0〕 But total revenue of $3.38 million fell short of the published ~$4.20 million consensus, while EPS of $(0.99) was slightly worse than the roughly $(0.97) expectation. The miss was driven largely by lower license revenue, not by a collapse in product sales.
The company is conceding that its current launch spending is too high for the pace of adoption. SG&A rose to $35.8 million in the quarter from $27.6 million a year earlier, while product sales remain only $2.6 million. LENZ is responding with a strategic reorganization expected to cut projected 2027 annualized operating expenses by more than 50%, to approximately $70 million-$75 million excluding stock compensation. That improves capital efficiency and extends the runway, but it also signals that management no longer intends to fund the original commercial buildout at its previous scale.
The CEO transition adds execution uncertainty to an already compressed strategy. Eef Schimmelpennink will leave the CEO role on December 1, 2026, with CFO Dan Chevallard becoming interim CEO. 〔1〕 The handoff is planned and Schimmelpennink will remain as a strategic advisor, so this is not an abrupt separation; nevertheless, it arrives alongside the reorganization and makes the next phase of VIZZ commercialization more dependent on interim leadership.
The balance sheet still gives LENZ room to execute the reset. Cash and cash equivalents were $30.6 million and marketable securities were $166.8 million at September 30, 2026, while total liabilities were $17.8 million. The company therefore has substantial liquid resources relative to its liabilities, but its nine-month net loss reached $104.4 million, underscoring why reducing the expense base has become central to the business story.
Bottom line: VIZZ adoption is improving, but not fast enough to offset the revenue mix shift and high launch costs. The filing is a negative earnings surprise paired with a meaningful strategic reset: LENZ is narrowing spending and changing leadership before the commercial model is proven.
Q3 earnings call, October 29
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!